Leukopenia and thrombocytopenia induced by etanercept: Two case reports and literature review

Página do item simplificado
dc.contributor.authorAzevedo V.F.
dc.contributor.authorSilva M.B.G.
dc.contributor.authorMarinello D.K.
dc.contributor.authordos Santos F.D.
dc.contributor.authorSilva G.B.G.
dc.date.accessioned2024-03-13T01:09:26Z
dc.date.available2024-03-13T01:09:26Z
dc.date.issued2012
dc.description.abstractTumor necrosis factor-alpha (TNF-alpha) is a proinflammatory cytokine, and its excess can lead to severe consequences. Those effects are known to be antagonized by TNF-alpha inhibitors. Etanercept is a fusion protein that inhibits TNF-alpha action. As TNF-alpha regulation is related to cellular differentiation of various cellular types involved in immune response through expression of several other cytokines, it is possible that the use of its inhibitors may cause cytopenia. We report two cases of bicytopenia induced by etanercept. Both cases recovered after drug withdrawal. We discuss the need of introduction of routine laboratorial tests in patients using anti-TNF therapy, in order to identify possible hematological changes. © 2012 Elsevier Editora Ltda. All rights reserved.
dc.description.firstpage107
dc.description.issuenumber1
dc.description.lastpage112
dc.description.volume52
dc.identifier.issn0482-5004
dc.identifier.urihttps://dspace.mackenzie.br/handle/10899/36885
dc.relation.ispartofRevista Brasileira de Reumatologia
dc.rightsAcesso Restrito
dc.subject.otherlanguageBiological products
dc.subject.otherlanguageBiological therapy
dc.subject.otherlanguageLeukopenia
dc.subject.otherlanguageNeutropenia
dc.subject.otherlanguageThrombocytopenia
dc.titleLeukopenia and thrombocytopenia induced by etanercept: Two case reports and literature review
dc.typeArtigo de revisão
local.scopus.citations20
local.scopus.eid2-s2.0-84856666674
local.scopus.updated2024-05-01
local.scopus.urlhttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84856666674&origin=inward
Arquivos
Coleções
Artigos de periódico